2012
Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment
Addy P, Radhakrishnan R, Cortes J, D’Souza D. Comorbid Alcohol, Cannabis, and Cocaine Use Disorders in Schizophrenia: Epidemiology, Consequences, Mechanisms, and Treatment. FOCUS The Journal Of Lifelong Learning In Psychiatry 2012, 10: 140-153. DOI: 10.1176/appi.focus.10.2.140.Peer-Reviewed Original ResearchComorbid substance use disorderSubstance use disordersUse disordersSubstance abuseHigh rateTreatment of schizophreniaCo-occurring disordersCourse of schizophreniaCocaine use disorderSelf-medication hypothesisCombination pharmacotherapyComorbid alcoholService utilizationLow compliancePatientsSchizophreniaSubstance useDisordersTreatmentDSM definitionCliniciansEpidemiologyThorough assessmentCannabisLatest findings
1999
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists
Krystal J, Belger A, D'Souza D, Anand A, Charney D, Aghajanian G, Moghaddam B. Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists. Neuropsychopharmacology 1999, 21: s143-s157. DOI: 10.1016/s0893-133x(99)00102-5.Peer-Reviewed Original ResearchHealthy human subjectsNMDA antagonist effectsNMDA antagonistsClinical studiesMetabotropic glutamate receptor agonistN-methyl-D-aspartate (NMDA) subtypeD2 receptor blockadeGlutamate receptor agonistsD2 receptor stimulationDopamine 2 receptorNovel pharmacologic strategiesEffects of ketaminePathophysiology of schizophreniaCourse of schizophreniaNovel pharmacotherapeutic strategiesHuman subjectsHyperglutamatergic stateSerotonin 2AGlutamate neuronsGlutamate releaseCerebral cortexPharmacologic strategiesCurrent antipsychoticsPharmacotherapeutic strategiesSubanesthetic doses